Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib

医学 奥西默替尼 化疗 内科学 贝伐单抗 肿瘤科 肺癌 免疫疗法 危险系数 化疗方案 养生 癌症 置信区间 表皮生长因子受体 埃罗替尼
作者
Maya N. White,Andrew J. Piper‐Vallillo,Rebecca M. Gardner,Kristen Cunanan,Joel W. Neal,Millie Das,Sukhmani K. Padda,Kavitha Ramchandran,Thomas T. Chen,Lecia V. Sequist,Zofia Piotrowska,Heather A. Wakelee
出处
期刊:Clinical Lung Cancer [Elsevier BV]
卷期号:23 (3): e210-e221 被引量:17
标识
DOI:10.1016/j.cllc.2021.11.001
摘要

Patients with EGFR-mutant lung cancer who have had disease progression on osimertinib commonly receive platinum doublet chemotherapy, but whether adding immunotherapy or bevacizumab provides additional benefit is unknown.This was a retrospective analysis at 2 university-affiliated institutions. Patients with EGFR-mutant lung cancer who had progression on osimertinib and received next-line therapy with platinum doublet chemotherapy (chemo), platinum doublet chemotherapy plus immunotherapy (chemo-IO), or platinum doublet chemotherapy plus bevacizumab (chemo-bev), were identified; patients who continued osimertinib with these regimens were included. Efficacy outcomes including duration on treatment (DOT) and overall survival (OS) from the start of chemotherapy were assessed. Associations of treatment regimen with outcomes were evaluated using adjusted Cox regression models, using pairwise comparisons between groups.104 patients were included: 57 received chemo, 12 received chemo-IO, and 35 received chemo-bev. In adjusted models, patients who received chemo-IO had worse OS than did those who received chemo (hazard ratio (HR) 2.66, 95% CI 1.25-5.65; P= .011) or those who received chemo-bev (HR 2.37, 95% CI 1.09-5.65; P= .030). A statistically significant difference in OS could not be detected in patients who received chemo-bev versus those who received chemo (HR 1.50, 95% CI 0.84-2.69; P= .17).In this retrospective study, giving immunotherapy with platinum doublet chemotherapy after progression on osimertinib was associated with a worse OS compared with platinum doublet chemotherapy alone. Platinum doublet chemotherapy without immunotherapy (with consideration of continuation of osimertinib, in selected cases) is a reasonable choice in this setting, while we await results of clinical trials examining optimal next-line chemotherapy-based regimens in EGFR-mutant lung cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Wali发布了新的文献求助10
1秒前
GIN的应助被zzk采纳,获得10
1秒前
2秒前
2秒前
天霸完成签到,获得积分20
3秒前
CodeCraft的应助被ZRH采纳,获得10
3秒前
白术发布了新的文献求助10
3秒前
3秒前
3秒前
李茗慧完成签到 ,获得积分10
3秒前
完美世界的应助被悦耳皮带采纳,获得10
4秒前
科研通AI6.3的应助被CYLiu采纳,获得10
5秒前
Rauf发布了新的文献求助10
6秒前
xty发布了新的文献求助10
6秒前
Az驳回了yyds的应助
7秒前
科研通AI6.3的应助被FionaZhang采纳,获得10
7秒前
8秒前
8秒前
yyy完成签到 ,获得积分10
8秒前
YAM完成签到 ,获得积分10
9秒前
luoshiwen发布了新的文献求助10
9秒前
Wali完成签到,获得积分10
9秒前
埃及舞发布了新的文献求助10
9秒前
JamesPei的应助被无溪现龙采纳,获得10
9秒前
乌贼爱吃发布了新的文献求助10
10秒前
10秒前
微信研友发布了新的文献求助10
10秒前
xhj666完成签到,获得积分10
10秒前
11秒前
JJyue发布了新的文献求助50
11秒前
wy完成签到,获得积分10
12秒前
arizaki7发布了新的文献求助10
13秒前
王一硕发布了新的文献求助10
13秒前
留蓝发布了新的文献求助10
14秒前
Owen的应助被夏梓硕采纳,获得10
14秒前
周林发布了新的文献求助10
15秒前
15秒前
wl完成签到,获得积分10
16秒前
humble发布了新的文献求助10
16秒前
羊羊羊完成签到,获得积分20
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193348
求助须知:如何正确求助?哪些是违规求助? 9579548
关于积分的说明 21866040
捐赠科研通 7792906
什么是DOI,文献DOI怎么找? 3437242
关于科研通互助平台的介绍 2560702
邀请新用户注册赠送积分活动 2484066